Sun Pharma subsidiary partners with Aclaris Therapeutics for licensing agreement

As per the pact, Aclaris grants Sun Pharma exclusive rights to specific patents for using deuruxolitinib, Sun Pharma's JAK inhibitor, or other isotopic forms of ruxolitinib, specifically for treating alopecia areata (AA) or androgenetic alopecia (AGA).
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news